Keywords
Diagnosis
Serology
How to Cite
Abstract
Leprosy is a chronic and infectious disease caused by Mycobacterium leprae (M. leprae). It has high infectivity and low pathogenicity. The aim of this study was to report the identification of a patient with multibacillary leprosy using the serological test (LID) during an active search. A 54-year-old male patient, living in Governador Valadares, Minas Gerais, Brazil, from the active search of the Leprosy
Research Center (NuPqHans/UFJF-GV), presented a positive serological test for recombinant bacillus proteins (ML0405/ML2331). He was referred to the Reference Center for Endemic Diseases and Special Programs (CREDENPES), complaining of skin lesions and nodules all over his body, and reported a history of head trauma, occasional dizziness, numbness in his feet, and nosebleeds. The patient presented positive bacilloscopy and biopsy results, concluding the diagnosis of multibacillary leprosy and receiving the indicated multidrug therapy. After three months of treatment, there was a reduction in the area/diameter of the lesions on the abdomen, indicating the effectiveness of the treatment. The positive result of the serological test (LID) allowed the identification of a multibacillary patient, who until then had not been diagnosed with leprosy. In addition, the use of the LID serological test in active search activities in endemic areas for early diagnosis can contribute to the zero-leprosy concept stipulated by the World Health Organization.
References
1. Ministério da Saúde (BR), Secretaria de Vigilância em Saúde, Departamento de Vigilância das Doenças Transmissíveis. Diretrizes para vigilância, atenção e eliminação da Hanseníase como problema de saúde pública: manual técnico-operacional. Brasília, DF: Ministério da Saúde; 2016.
2. Ministério da Saúde (BR), Secretaria de Vigilância em Saúde. Boletim Epidemiológico de Hanseníase[Internet]. Brasília: Ministério da Saúde; jan. 2022. [acesso em 24 jan. 2023]. Disponível em: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/especiais/2022/boletim-epidemiologicode-hanseniase-_-25-01-2022.pdf.
3. Bahmanyar ER, Smith WC, Brennan P, Cummings R, Duthie M, Richardus JH, et al. Leprosy diagnostic test development as a prerequisite towards elimination: requirements from the user’s perspective. PLoS Negl Trop Dis. 2016;10:e0004331. doi: https://doi.org/10.1371/journal.pntd.0004331.
4. Amorim FM, Nobre ML, Ferreira LC, Nascimento LS, Miranda AM, Monteiro GR, et al. Identifying Leprosy and Those at Risk of Developing Leprosy by Detection of Antibodies against LID-1 and LID-NDO. PLoS Negl Trop Dis. 2016;10(9):e0004934. doi: https://doi.org/10.1371/journal.pntd.0004934.
5. DuVall AS, Fairley JK, Sutherland L, Bustinduy AL, Mungai PL, Muchiri EM, et al. Development of a specimen-sparing multichannel bead assay to detect antiparasite IgG4 for the diagnosis of Schistosoma and Wuchereria infections on the coast of Kenya. Am J Trop Med Hyg. 2014;90(4):638-45. doi: https://doi.org/10.4269/ajtmh.13-0292.
6. O’Hearn AE, Voorhees MA, Fetterer DP, Wauquier N, Coomber MR, Bangura J, et al. Serosurveillance of viral pathogens circulating in West Africa. Virol J. 2016;13(1):163. doi: https://doi.org/10.1186/s12985-016-0621-4.
7. Marçal PHF, Fraga LAO, Matos AMM, Menegati L, Coelho ACO, Olmo R, et al. Utility of immunoglobulin isotypes against LID-1 and NDO-LID for, particularly IgG1, confirming the diagnosis of multibacillary leprosy. Mem Inst Oswaldo Cruz. 2018;113(5):e170467. doi: https://doi.org/10.1590/0074-02760170467.
8. Won KY, Kanyi HM, Mwende FM, Wiegand RE, Goodhew EB, Priest JW, et al. Multiplex Serologic Assessment of Schistosomiasis in Western Kenya: Antibody Responses in Preschool Aged Children as a Measure of Reduced Transmission. Am J Trop Med Hyg. 2017;96(6):1460-10.4269/ajtmh.16-0665.7. doi: https://doi.org/10.4269/ajtmh.16-0665.
9. BRASIL. Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde. Portaria SCTIE/MS nº 67, de 7 de julho de 2022. Torna pública a decisão de aprovar, no âmbito do Sistema Único de Saúde – SUS, o Protocolo Clínico e Diretrizes Terapêuticas da Hanseníase. Brasília, DF, 07 jul. 2022. [acesso em 24 jan. 2023]. Disponível em: https://www.gov.br/conitec/pt-br/midias/protocolos/20220818_pcdt_hanseniase.pdf.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Heloine Martins Leite, Marcos Daniel Silva Pinheiro, Daisy Cristina Monteiro dos Santos, Karolina Dias Campos, Lorena Bruna Pereira de Oliveira, Lucia Alves de Oliveira Fraga
Downloads
